CHMP recommends for approval generic version of Atripla

Share:

At its June meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.

Summary of opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is available here.

Скачать (PDF, 64KB)

Source

 

Share: